Wolowacz S, Briggs A, Lloyd AJ, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2016 ISPOR 19th Annual European Congress; October 29, 2016. Vienna, Austria.
Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016 Sep;19(2016):704-19. doi: 10.1016/j.jval.2016.06.001
Twiss J, Doward LC, McKenna SP, Eckert B. Interpreting scores on the multiple sclerosis-specific PRIMUS and U-FIS outcome measures. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A373. doi: 10.1016/S1098-3015(10)74836-1
Meads DM, Doward LC, McKenna SP, Fisk J, Twiss J, Eckert B. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler. 2009 Oct 1;15(10):1228-38. doi: 10.1177/1352458509106714
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler. 2009 Sep 1;15(9):1092-102.
Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, Veale DJ. The development of the L-QoL: a quality of life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009 Feb;68(2):196-200. doi: 10.1136/ard.2007.086009
Doward LC, McKenna SP, Meads DM, Kahler K, Frech F. The development of the Herpes Symptom Checklist (HSC) and the Herpes Outbreak Impact Questionnaire (HOIQ). Value Health. 2009 Jan 1;12(1):139-45.
Holmes SJ, McKenna SP, Doward LC, Hunt SM, Shalet SM. Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency. Endocrinology and metabolism. 1995 Jan 1;2(1):63-9.
McKenna SP, Doward LC. Quality-of-life assessment of adults with growth hormone deficiency: implications for drug therapy. Pharmacoeconomics. 1994 Nov 1;6(5):434-41.
Doward LC. Developing a measure of quality of life for patients with recurrent genital herpes. Drug Inf J. 1994 Jan 1;28(1):19-25.